For efficient monitoring of the new transgene constructs expression, it is necessary not only to monitor their life-time distribution within a whole body, but also their spatial distribution within tissues and cells as well as location within bio-macromolecular assemblies. This is accomplished through either labeling with antibodies tagged with reporter molecules or expressing fusion proteins containing reporting domains. Unfortunately, the imager allowing us to reveal the transgene products over such a wide spectrum of approaches does not exist. Hence, there is a strong need for correlations between various imaging modes [1] . Recently, we bioengineered the recombinant single-chain variable fragment (scFv) antibodies designed for simultaneous detection with magnetic resonance imaging (MRI) and positron emission tomography (PET) followed by molecular imaging with electron energy loss spectroscopy (EELS) [2] . In our previous work, we bioengineered the plasmid constructs driving organelle targeted expression of the transgene for a fusion protein with the integrated reporter molecules [3] . Here, we report the results of bioengineering of the constructs for transgenes, which products are detectable with MRI, fluorescence, and EELS.
Figure legends.
The transgene constructs for fusion protein (occludin and integrated reporter molecule) were expressed in cultured human umbilical vein endothelial cells (HUVEC). The images were acquired with ultra-low-light, wide-field, computer deconvolution fluorescence microscopy. Horizontal field width = 50 microns.
